NCT05672225 Two-channel IV-PCA With Dexmedetomidine
| NCT ID | NCT05672225 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Korea University Guro Hospital |
| Condition | Analgesia, Patient-Controlled |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2023-02-07 |
| Primary Completion | 2025-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 110 participants in total. It began in 2023-02-07 with a primary completion date of 2025-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dexmedetomidine was administered in the 'selector' channel and fentanyl in the 'basic \& bolus' channel of dual channel intravenous patient-controlled analgesia (IV-PCA) and the amount of opioid consumption was compared. In addition, intensity of pain, postoperative nausea/vomiting, and postoperative delirium was evaluated.
Eligibility Criteria
Inclusion Criteria: * Patients who was scheduled for laparoscopic major abdominal surgery (Gastrectomy, Hepatectomy, Colectomy, Pancreatectomy) under general anesthesia * Aged ≥ 20 years old Exclusion Criteria: * Body mass index ≥35 kg/m2 * American Society of Anesthesiologists physical status \> 3 * Severe cardiovascular disorder * Severe liver or renal dysfunction * Preoperative dyspnea * Contraindication to dexmedetomidine (preoperative severe bradycardia (Heart rate \<50), atrioventricular block, allergy to dexmedetomidine) * Preoperative use of opioid, anticonvulsant, antidepressant
Contact & Investigator
Seok Kyeong Oh, M.D., Ph.D
PRINCIPAL INVESTIGATOR
Korea University Guro Hospital
Frequently Asked Questions
Who can join the NCT05672225 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Analgesia, Patient-Controlled. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05672225 currently recruiting?
Yes, NCT05672225 is actively recruiting participants. Contact the research team at nanprayboy@korea.ac.kr for enrollment information.
Where is the NCT05672225 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05672225 clinical trial?
NCT05672225 is sponsored by Korea University Guro Hospital. The principal investigator is Seok Kyeong Oh, M.D., Ph.D at Korea University Guro Hospital. The trial plans to enroll 110 participants.